Company ProfilePremium

ChemOn Inc.

Company Profile Analysis

Ticker: 166480.KQ코아스템켐온 주식회사

ESOMAR 23 Corporate BadgeISO Certifications Badge
ChemOn Inc. - Company showcase

Year Founded & Workforce

2003

391 Employees

ChemOn Inc. logo

ChemOn Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

ChemOn Inc. Overview

CorestemChemon is a small-cap Korean "hybrid" biotech that pairs a revenue-generating non-clinical CRO (the former ChemOn, founded in 2000 as Korea's first private GLP safety-testing laboratory) with a high-risk stem-cell drug developer (the former Corestem). The CRO division performs toxicology, safety pharmacology, efficacy and bioanalytical studies for drug, biologic, medical-device, food and chemical developers, historically running 1,000–1,500 studies per year, and supplies essentially all group revenue. The drug division's sole marketed product, NeuroNata-R (lenzumestrocel), is an autologous bone-marrow mesenchymal stem-cell therapy for ALS conditionally approved in Korea in 2014; its global Phase 3 missed its primary endpoint in December 2024, but Korea's MFDS approved a narrowed label for slow-progressing patients in May 2026. The company is loss-making (FY2025 operating loss KRW 21.2 bn on revenue of KRW 20.2 bn), thinly capitalised, and its equity story hinges on CRO recovery and a US BLA targeted for 2027.


Company's own description

In its investor materials CorestemChemon describes itself as a "Total Health Care Company" possessing a full-cycle drug-development system — from early non-clinical experimentation through Phase 1–3 clinical capability — with a stated vision of improving quality of life through new-drug development (IR decks, April/June 2024). The company frames the 2022 merger around three pillars: an in-house non-clinical database spanning early experiments to Phase 3 entry, financial stabilisation via the CRO's recurring revenue, and scientific synergy between the CRO's testing infrastructure and the stem-cell pipeline.

In its FY2025 business report (as summarised by IB Tomato, April 2026), the company attributes the revenue decline to reduced CRO testing orders amid a global downturn and a prolonged slump in Korea's bio-industry, and to the suspension of NeuroNata-R manufacturing after Q1 2025 pending new-site certification and a label-change application.

Independent characterisation

Functionally, CorestemChemon is a Korean non-clinical CRO carrying a binary stem-cell option:

Economic engine: The CRO division (former ChemOn) is a fixed-cost-heavy service business — GLP facilities, specialist toxicologists and pathologists, animal husbandry — whose gross margin swings sharply with utilisation. thebell (Sep 2026) notes that when utilisation is low the cost-of-sales ratio exceeds 100%, but incremental revenue drops largely to gross profit. In Q1 2026 the cost-of-sales ratio was 136%; in Q2 2026 it improved to 102.5%.

Option value: NeuroNata-R is an autologous, intrathecally administered cell therapy for ALS with ~400+ patients treated in Korea since 2014 (Money Today, Jun 2026). Its value depends on (i) domestic commercial restart from the new Osong plant and (ii) a US path via FDA Type C → RMAT → BLA.

Balance-sheet constraint: Cash of only KRW 2.1 bn at end-FY2025 against KRW 24.1 bn of borrowings due within a year (IB Tomato, Apr 2026) makes the CRO recovery an existential, not merely incremental, variable.

Revenue model

Revenue typeDescriptionShare of revenueSource
Contract research services (fee-for-study)Non-clinical safety/efficacy studies billed per contract, recognised over time by percentage of completion98% of H1 2026 revenue (KRW 9.5 bn of 9.7 bn); ~98% of FY2025thebell Sep 2026; IB Tomato Apr 2026
Product sales (cell therapy)NeuroNata-R manufactured per patient (autologous) and sold in Korea~1% of FY2025 (≈KRW 0.2 bn); ~4% of FY2024 (≈KRW 1.1 bn); 13% in FY2019 (pre-merger consolidated)IB Tomato; SK Securities 2020
Licensing / technology transferHistorically minimal (1% in FY2019); management cites prospective pre-approval out-licensing of NeuroNata-R as a contingent funding source~0% currentlySK Securities 2020; IB Tomato
Government R&D grantsNational project funding (≥KRW 5.4 bn secured in 2026) — booked within CRO activityIncluded in CRO ordersthebell Sep 2026
Subscription—0%—

Value-chain position, customers and end-markets

Value chain: The CRO sits between discovery/lead optimisation and first-in-human trials, generating the GLP safety package required for IND/CTA filings. Through a 2021-era MOU with clinical CRO Dream CIS (signed by then-ChemOn CEO Song Si-hwan), ChemOn positioned itself to offer an integrated non-clinical-to-clinical service (Daily Pharm).

Customer types: Korean pharma and biotech developers, medical-device makers, functional-food and cosmetics-ingredient developers, chemical registrants, government research programmes, and — increasingly — overseas institutions (a contract with a Vietnamese university hospital in 2026).

Substance mix: The September 2024 IR deck's chart of studies by test-article type shows the largest single category at 46.5% of studies (understood to be synthetic pharmaceuticals), with the balance across biologics, chemicals, food/health-functional food, cosmetics, natural-product drugs, medical devices and nanomaterials (0.2%). Exact mapping of the remaining percentages could not be reliably extracted.

End-markets: Korean drug and device R&D (dominant); emerging adjacent-industry testing (functional foods, cosmetics materials); ALS therapeutics (drug division).

Strategy

Stated strategic themes (company IR and management statements)

  1. Full-cycle drug development ("Total Health Care Company"): leverage in-house non-clinical capability to accelerate the stem-cell pipeline from discovery to Phase 3.

  2. CRO as self-funding engine: restore CRO quarterly revenue to KRW 10 bn+, at which level management says all personnel and operating costs are covered (thebell, Jan 2026); first-order target is a return to quarterly gross profit (thebell, Sep 2026).

  3. Precision-targeted NeuroNata-R: narrow the label to slow progressors (achieved in Korea, May 2026), restart commercial production at Osong, then pursue US RMAT designation and a BLA without an additional trial.

  4. Diversification of CRO end-markets: medical devices, functional foods, cosmetics materials, overseas customers.

  5. Cell & gene therapy CDMO: expand contract manufacturing and development from the Osong base (thebell series, Sep 2026).

Initiatives in the last 24 months

InitiativeDateDetailStatus
Osong ATMP centre commissioning2024–2026600 lots/year; permits obtained; comparability study pendingIn progress
NeuroNata-R label changeApr 2025–May 2026Restricted to slow progressorsApproved May 2026
Rights offering & deleveragingAug–Nov 2025~KRW 26.1 bn raised; KRW 19.1 bn for debt repaymentCompleted
US regulatory pathwayAug 2026 → 2027FDA Type C requested (9 items); RMAT then BLA targeted 2027; ~KRW 5.5 bn earmarked for FDA filing costsMeeting expected before end-Oct 2026
US research collaboration2025–2026First Korean company in WFIRM-led, NSF-backed regenerative-medicine initiativeOngoing
National R&D projects2,026≥KRW 5.4 bn incl. antibody immunotoxicity (KRW 3.0 bn), stem-cell embryo-development alternative tox (KRW 0.6 bn)Awarded
Overseas CRO expansion2,026Vietnamese university hospital contractSigned
Adjacent-industry testing2025–2026Functional food and cosmetic materialsOngoing

ESG/sustainability commitments: none identified. Cost programmes with targets: none disclosed beyond gross-margin breakeven goal.

Medium-term targets / guidance

No formal financial guidance is issued. Management statements: (i) CRO quarterly revenue ≥ KRW 10 bn as breakeven anchor; (ii) BLA submission in 2027; (iii) company estimate of ≥KRW 500 bn annual US sales potential if FDA-approved (Money Today, Apr 2026) — aspirational, not guidance.

Products & Services

Non-clinical CRO Division (former ChemOn)

Service lineDescription / capabilitiesTarget customerNotes
General toxicitySingle- and repeat-dose toxicity studies in rodents and non-rodents under GLPDrug, biologic, chemical developersCore regulatory package for IND
Genetic toxicityIn vitro and in vivo genotoxicity batteriesDrug and chemical developers—
Reproductive & developmental toxicityFertility, embryo-foetal and pre/post-natal studiesDrug developers2026 national project on stem-cell-based embryo-development alternative tox (KRW 0.6 bn)
CarcinogenicityLong-term bioassaysDrug developersMulti-year contracts; revenue recognition extends into 2027+ (thebell, Sep 2026)
Safety pharmacologyCNS, cardiovascular, respiratory and general pharmacology studiesDrug developers—
Efficacy (pharmacology) testingStudy design, execution and model development for efficacy evaluationBiotech, academia—
Disease-model animalsProduction and sale of disease-model animalsResearchersListed in IR deck
Alternative / advanced methodsIn vitro and in vivo toxicity tests; advanced alternative test methodsCosmetics, chemicals, pharmaAligns with global animal-replacement trends
Immunotoxicity for biologicsPredictive immunotoxicity evaluation of antibody drugsBiologic developers2026 national project worth KRW 3.0 bn
PathologyHistopathology and clinical pathologyAll study sponsors—
Bioanalysis & material analysisTest-article analysis, biological sample analysisAll study sponsors—
Medical-device testingBiocompatibility and safety testingDevice makersFastest-growing demand segment in 2026 (Money Today, Jun 2026)
Functional food & cosmetics materials testingSafety/efficacy testing for adjacent industriesFood, cosmetics firmsPortfolio diversification initiative (IB Tomato, Apr 2026)
SEND data servicesInstem-based SEND-compliant dataset creation for regulatory submissionSponsors filing with FDAChemOn deployed Instem's preclinical suite and submit™ software via SaaS (CB Insights)

Throughput: 1,000–1,500 studies per year (IR deck, Sep 2024). Pricing: per-study, not publicly disclosed.

Bio-pharmaceutical Division (former Corestem)

Product / candidateCell typeIndicationStage (latest)Partners / sitesSource
NeuroNata-R (lenzumestrocel)Autologous BM-MSC, intrathecalALS (slow-progressor subgroup after May 2026 label change)Marketed in Korea (conditional 2014; label amended May 2026); US BLA targeted 2027Hanyang University + 4 institutionsIR deck; Money Today
Artificial CSFNeuroNata-R excipientFormulation componentUnder formal review per 2024 IR timeline—IR deck
CE111BR16MSCMultiple system atrophy (MSA)Phase 1 completedHanyang UniversityIR deck
CE211BR19MSCCerebellar ataxiaPhase 1 completedYonsei SeveranceIR deck
CE211NS21 (also cited as CE211N21)Allogeneic BM-MSCNeuromyelitis optica (NMO)Phase 1 protocol submitted (2024)SNU, Yonsei, Hanyang, Kyung HeeIR deck
Astrocyte programmeiPSC / ESCParkinson's diseasePreclinical—IR deck
CE211AT15MSCSystemic lupus erythematosusPhase 1 completed; investigator-initiated trial completedHanyang University, Asan Medical CenterIR deck
EV231LU20Extracellular vesiclesFibrosisPreclinicalCorestemChemonIR deck

NeuroNata-R detail:

Mechanism: Patient's own bone-marrow-derived mesenchymal stem cells, with anti-inflammatory and immunomodulatory properties; company highlights MCP-1 (CNS-inflammation chemokine) and NfL (neurofilament light, neuronal-damage biomarker) changes.

Phase 3 (ALSUMMIT) design: 126 early-to-moderate ALS patients; double-blind, randomised, multicentre, placebo-controlled; Group 1 (26 treated), Group 2 (50 treated), Group 3 (50 control); bone-marrow extraction and repeated intrathecal injections over 12+ months with 36-month observational follow-up (IR deck, Sep 2024).

Results: Primary endpoints (Joint Rank Score incorporating ALSFRS-R and survival) not met: Group 2 vs control at 12 months p=0.118; Group 1 vs control at 6 months p=0.339 (Finance Scope, 18 Dec 2024). Company-reported post-hoc: slow-progressor subgroup met CAFS (primary) and ALSFRS-R (secondary) endpoints, with consistent SVC improvement and NfL reduction (Money Today, Jun 2026).

Commercial history: Supplied to 400+ patients in Korea; foreign patients represented ~60% of prescriptions in 2019, largely referred from US academic centres (SK Securities, Aug 2020).

Pricing: Not publicly disclosed for Korea. Company US model assumed ~KRW 100 m per administration and ~KRW 500 m per patient per year, implying ≥KRW 500 bn US annual sales at ~1,000 patients (IR deck, Sep 2024) — management projection, not guidance.

Financial Narrative

All figures consolidated, K-IFRS, KRW bn. FY2021–FY2022 include ChemOn as a 53% subsidiary; FY2023 onward reflect the merged entity. Source: Butler (DART-derived) unless noted.

Income statement

Margins and growth rates derived from reported figures. Revenue CAGR FY2021–FY2025: -9.6% (derived).

Commentary. FY2022's revenue spike to KRW 46.3 bn coincided with strong COVID-era vaccine/therapeutic non-clinical demand (ChemOn had performed non-clinical work on Korean COVID-19 vaccines and treatments, per the Dream CIS MOU announcement) and Korea's biotech funding peak; FY2022's small positive net income despite an operating loss reflects non-operating items not detailed in sources reviewed. From FY2023 the Korean biotech funding drought cut CRO orders, while Phase 3 costs and post-merger overhead widened losses. FY2025 marked the trough: CRO revenue fell 28% to KRW 19.8 bn, NeuroNata-R production stopped, and operating losses exceeded revenue. The FY2024 net loss also absorbed financing costs on convertible and exchangeable bonds; the FY2025 net loss included the full KRW 3.9 bn impairment of CRO merger goodwill (IB Tomato).

Interim trend: notes and sources

Sources: Daily Pharm (Aug 2025: H1 2025 op loss KRW 10.7 bn, revenue down 25% from KRW 15.5 bn); thebell (Oct 2025: op loss widened 25% YoY → H1 2024 ≈ KRW 8.6 bn derived; OCF -KRW 7.8 bn); thebell (Sep 2026: H1 2026 KRW 9.7 bn revenue, KRW 10.2 bn op loss; Bizwatch reports KRW 10.3 bn).

Source: thebell, Sep 2026. Q2 revenue +24.2% QoQ; gross loss narrowed 91.4%.

Balance sheet

Sources: Digital Today (FY2024 balance sheet from DART); IB Tomato (FY2025 cash, borrowings, goodwill). FY2025 equity derived from market cap ÷ PBR (KRW 100.5 bn ÷ 2.26) and is approximate.

Total debt: Short-term debt due within one year KRW 24.1 bn at end-FY2025; long-term (non-current) borrowings not disclosed in sources reviewed. Facility loans are partly secured on assets.

Net debt: at least KRW 22.0 bn (current borrowings minus cash; excludes non-current debt and bonds) — derived, understated.

Working capital: negative at end-FY2025 given current borrowings > 10× cash (derived qualitative).

Goodwill: Original KRW 3.9 bn fully impaired by FY2025.

Commentary. The November 2025 rights issue (~KRW 26.1 bn) was predominantly allocated to debt repayment (KRW 19.1 bn, of which KRW 17.3 bn executed) with KRW 6.3 bn for operations (KRW 2.1 bn used, KRW 4.2 bn remaining) (IB Tomato, Apr 2026). Despite this, cash at year-end was KRW 2.1 bn — signalling that liquidity depends on CRO recovery in 2026. The company's securities registration statement named, in descending priority, CRO retained earnings, pre-approval NeuroNata-R out-licensing, and — as a worst case — sale of the Osong ATMP centre or the CRO division as repayment sources; management later said asset sales were not under consideration.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / services

Non-clinical CRO (R&D services)

Former ChemOn

General/genetic/reproductive toxicity, carcinogenicity, safety pharmacology, efficacy studies, pathology, bioanalysis, alternative-method testing, disease-model animals

Cell therapy (bio-pharmaceuticals)

Former Corestem

NeuroNata-R (marketed); clinical/preclinical MSC, iPSC/ESC and EV pipeline

Revenue by Segment

SegmentFY2023FY2024FY2025

Non-clinical CRO revenue (KRW Bn)

31.827.519.8

Cell therapy and other revenue (KRW Bn; FY2023 derived as residual)

1.91.30.4

Total revenue (KRW Bn)

33.728.820.2

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (%) and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

CRO share of total revenue (%)

94.495.598.0

CRO revenue YoY growth (%)

—-13.5-28.0

Cell therapy revenue YoY growth (%, reported basis)

——-80

Revenue by Segment (Half-Yearly)

MetricH1 2024H1 2025H1 2026

Total revenue (KRW Bn)

15.511.69.7

CRO revenue (KRW Bn)

14.911.39.5

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

30.246.333.728.820.2

Operating income (KRW Bn)

-10.5-6.0-19.7-22.0-21.2

Net income (KRW Bn)

-5.01.0-17.7-26.3-26.8

Revenue YoY growth (%)

—53.3-27.2-14.5-29.9

Operating margin (%)

-34.8-13.0-58.5-76.4-105.0

Net margin (%)

-16.62.2-52.5-91.3-132.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricH1 2024H1 2025H1 2026

Revenue (KRW Bn)

15.511.69.7

Operating loss (KRW Bn)

-8.6-10.7-10.2

Operating cash flow (KRW Bn)

—-7.8—

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2026Q2 2026

Revenue (KRW Bn)

4.35.4

Cost-of-sales ratio (%)

136.0102.5

Gross profit (KRW Bn)

-1.564-0.130

Balance Sheet

MetricFY2024FY2025

Total assets (KRW Bn)

117.5—

Total liabilities (KRW Bn)

68.9—

Total equity (KRW Bn)

48.644.5

Cash and cash equivalents (KRW Bn)

—2.1

Short-term borrowings (KRW Bn)

—11.2

Current portion of long-term borrowings (KRW Bn)

—12.9

Goodwill from ChemOn merger, carrying value (KRW Bn)

—0.0

Financial Analysis

MetricDetail

Operating cash flow

Negative in recent years; H1 2025: -KRW 7.8 bn (thebell)

Capex

Osong cGMP/ATMP centre built Apr 2023–Aug 2024; total cost not disclosed in sources reviewed; residual equipment payments funded from 2025 offering

Free cash flow

Negative (derived from negative OCF and capex)

Buybacks

No buyback programme identified; treasury shares (4.78%) have been used as underlying for exchangeable bonds

Financial Analysis — ROE

RatioValueBasis

ROE

-62.6% (trailing)

Butler

ROA (FY2024)

≈ -22.4%

Derived: net loss 26.3 ÷ assets 117.5

Current ratio

Not publicly disclosed; implied well below 1.0× at FY2025

Derived qualitative

Liabilities / equity (FY2024)

141.8%

Derived: 68.9 ÷ 48.6

Net debt / EBITDA

Not meaningful (negative EBITDA)

—

Interest coverage

Negative (operating loss)

—

Asset turnover (FY2024)

0.25×

Derived: 28.8 ÷ 117.5

P/B

2.26×

Butler

Geography Overview

GeographyEvidenceTrend

Korea

CRO customers are predominantly Korean pharma/biotech/device firms and national R&D programmes; NeuroNata-R sold only in Korea

Declined FY2023–FY2025; orders recovering in 2026

Southeast Asia

Contract with a Vietnamese university hospital (2026)

New / nascent

United States

No revenue; North American subsidiary (2023) and North Carolina base for regulatory/commercial preparation; participation in a WFIRM-led, NSF-backed regenerative-medicine initiative

Pre-revenue

Foreign patients in Korea (historical)

~60% of NeuroNata-R prescriptions in 2019 were foreign patients treated in Korea

Halted with production suspension in 2025

Share Price & Returns

Reference pointPrice (KRW)Source

~16–22 Oct 2025

1,648–1,680

Digital Today

Rights offering prelim. issue price (Aug 2025)

1,890

Digital Today

Intraday reading, early Jun 2026 (post-MFDS approval)

~2,915

Money Today page quote

Latest aggregator quotes, Oct 2026

1,901–2,020

Butler

Valuation Multiples

MultipleCorestemChemonNote

P/E

Not meaningful (losses)

Butler

P/B

2.26×

Butler

EV/Sales (FY2025)

≈6.1×

Derived: (market cap 100.5 + ≥22.0 net current debt) ÷ revenue 20.2; understated EV

EV/EBITDA

Not meaningful (negative EBITDA)

—

Capital Markets

ItemStatus

Analyst consensus

None identified (company "Not Rated" historically by SK Securities; Korea IR Council sponsored research only)

Dividend history / policy

No dividends paid; no policy announced

Buyback authorisations

None identified

Treasury shares

4.78%; used to back exchangeable bonds (2nd–4th series exchanged Sep 2026)

Credit ratings (Moody's / S&P / Fitch)

None — not rated

Debt maturity profile

KRW 11.2 bn short-term borrowings + KRW 12.9 bn current portion of long-term borrowings due within 12 months of end-FY2025; longer maturities not disclosed

Equity raises

Nov 2025 shareholder rights offering ~KRW 26.1 bn (planned KRW 37.8 bn)

Analyst Conclusions

Management guidance

No formal numerical guidance. Management expects (i) CRO revenue recognition from H1 2026 orders to accelerate in H2 2026, with further cost-of-sales improvement; (ii) the first goal of a quarterly gross-profit turnaround; (iii) domestic NeuroNata-R commercial production after the Osong comparability study; (iv) FDA Type C meeting before end-October 2026 and a BLA in 2027.

Consensus

No sell-side consensus is available.

Bull case

  1. Operating leverage is real and visible. Q2 2026 revenue rose 24% QoQ and gross loss shrank 91%; with KRW 12.7 bn backlog and orders up 69%, a return to KRW 10 bn+ quarterly CRO revenue would, per management, cover company-wide fixed costs.

  2. Regulatory derisking in Korea. MFDS approval of the narrowed label (May 2026) validates the slow-progressor/biomarker thesis and enables commercial restart from an FDA-standard plant.

  3. Asymmetric US option. If FDA accepts a BLA on existing Phase 3 data (run under an FDA-cleared IND), even modest US uptake would dwarf the current ~KRW 100 bn market capitalisation.

Bear case

  1. Liquidity is the binding constraint. KRW 2.1 bn cash against KRW 24.1 bn near-term borrowings (end-FY2025) leaves little room for execution slippage; further dilution or asset sales are plausible.

  2. FDA scepticism toward post-hoc subgroups. Both pre-specified primary endpoints failed; FDA may require a confirmatory trial the company cannot fund.

  3. Structural underperformance in CRO. Peers grew 26–43% in H1 2026 while CorestemChemon's revenue fell 16%; goodwill impairment signals the acquired CRO earns less than expected.

Catalysts and monitorables (next 12 months)

  • FDA Type C meeting (expected by end-Oct 2026) and written minutes (~30 days later)

  • Q3 2026 results (Nov 2026): CRO revenue trajectory and whether quarterly gross profit turns positive

  • Osong comparability study completion and first commercial NeuroNata-R doses

  • FY2026 business report (Mar 2027): cash position, refinancing of current borrowings, KOSDAQ listing-criteria compliance

  • RMAT application/designation; any out-licensing negotiation

  • Further capital raises, EB/CB conversions, 5%+ holder changes

  • Korean biotech financing conditions and government R&D budgets

Analyst verdict

CorestemChemon is best understood not as the ChemOn CRO the original identifier pointed to, but as a distressed hybrid in which that CRO has become the life-support system for a stem-cell programme. The CRO franchise itself retains genuine assets: a 26-year GLP heritage, an AAALAC-accredited facility, a broad toxicology menu, and fresh evidence of demand recovery — H1 2026 orders of KRW 15.2 bn and a KRW 12.7 bn backlog. Because the business is overwhelmingly fixed-cost, the revenue rebound now under way should translate quickly into margin repair, as Q2 2026's collapse in gross loss demonstrates.

The problem is time and capital. Group revenue has fallen for three straight years to KRW 20.2 bn, operating losses have exceeded KRW 19 bn in each of the last three years, and year-end FY2025 cash covered less than a tenth of borrowings due within twelve months. The November 2025 rights issue bought time by repaying debt, not by building a cushion. Meanwhile, the ChemOn goodwill has been written to zero and the company is visibly trailing listed peers that are already growing double digits.

NeuroNata-R is a legitimate but low-probability option. The May 2026 Korean label approval keeps it alive and allows a commercial restart, yet the US path rests on post-hoc subgroup and biomarker arguments after a failed pivotal trial — historically a difficult case before FDA. The late-2026 Type C feedback is therefore the single most important near-term data point: a constructive response could support partnering and non-dilutive funding; a request for a new trial would likely force further dilution or a strategic sale of assets.

On balance, the investment case is speculative and event-driven. The CRO recovery provides a credible floor narrative only if it arrives fast enough to outrun the balance sheet. Monitor quarterly gross profit, debt refinancing and FDA minutes before assigning value to the drug option.


ItemStatus
ISIN, auditor, board committee structure, outside directors—
Executive compensation—
Annual gross profit, EBITDA, EPS, R&D expense, capex, FCF—
Geographic revenue split—
Patent count—
Top-10 institutional holders—
ESG ratings—
ChemOn standalone KOSDAQ listing date (217600)—
Exact merger completion dateConflicting (Dec 2022 per disclosures/press vs Dec 2023 per company IR deck)
Date of Corestem's original ChemOn stake acquisition—

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / notesBackgroundSource

Yang Gil-an (양길안)

Representative Director (CEO)

——

IR deck 2024; thebell 2026

Kim Kyung-suk (김경숙)

Standing Advisor; de facto controlling shareholder

Founder of Corestem (2003); CEO through at least 2022

Associated with Hanyang University College of Medicine (SK Securities, 2020)

Digital Today; SK Securities

Lee Tae-yong (이태용)

Director (non-registered/unregistered officer)

Since 1 Jan 2020

—

Digital Today (DART)

Kim Moon-soon (김문순)

Director

——

Digital Today (DART)

Song Si-hwan (송시환)

Former CEO of ChemOn (pre-merger)

——

Daily Pharm

Major Shareholders

HolderStakeDateSource

Kim Kyung-suk (common shares)

8.17% (2,687,133 shares)

21 Oct 2025

Digital Today (DART)

Kim Kyung-suk (including subscription rights)

10.21%

21 Oct 2025

Digital Today (DART)

Kim Kyung-suk & related parties

26.92% (historical)

2020

SK Securities

Seoul Global (venture fund, historical)

6.58%2020

SK Securities

Treasury shares

4.78%

Oct 2026

Butler

Lee Tae-yong (specified securities)

116,392

21 Oct 2025

Digital Today

Kim Moon-soon

2,352 (0.01%)

22 Oct 2025

Digital Today

Competitive Landscape

Key Competitors

CompetitorTypeH1 2026 revenue (KRW Bn)H1 2026 operating income (KRW Bn)Positioning vs CorestemChemonSource

Biotoxtech

Listed non-clinical CRO (closest pure-play peer)

26.3 (+26%)

-2.0

~2.7× CorestemChemon's revenue; recovering faster

Bizwatch

HLB Biostep

Listed non-clinical CRO

29.5 (-6%)

-4.5

Larger; losses narrowing

Bizwatch

Kolmar Biotech (formerly Woojung Bio)

Listed non-clinical CRO / bio

22.0 (+43%)

0.4

Returned to profit

Bizwatch

DT&CRO

Listed non-clinical CRO

21.4 (+6%)

-10.1

Similar loss scale

Bizwatch

Dream CIS

Listed clinical CRO (partner)

37.4 (+22%)

2.8

Clinical, profitable

Bizwatch

Korea Institute of Toxicology (KIT)

Government-funded GLP institute

Not applicable

Not applicable

Largest domestic GLP capacity; price/capacity benchmark

—

C&R Research

Clinical CRO

—

Profitable (H1 2025: KRW 1.0 bn)

Clinical segment

Daily Pharm

Bio-Infra

Clinical/bioanalytical

—

H1 2025: -3.3

—

Daily Pharm

Charles River Laboratories, Inotiv, WuXi AppTec, Pharmaron, JOINN

Global non-clinical CROs

——

Compete for Korean sponsors' FDA-bound GLP packages

—

Competitors by Segment

ProductCompanyTypeStatusSource

Riluzole

Sanofi (originator)

Small molecule, oral

Approved 1987 (per IR deck); generic

IR deck

Radicava / Radicut (edaravone)

Mitsubishi Tanabe Pharma

IV / oral

Approved US 2017; oral 2022

IR deck

Relyvrio

Amylyx

Oral

Conditional US approval 2022; withdrawn from market (2024)

IR deck

Qalsody (tofersen)

Biogen

Antisense, intrathecal

Accelerated approval 25 Apr 2023 for SOD1-ALS (~2% of patients)

IR deck

NurOwn

BrainStorm Cell Therapeutics

MSC-NTF cell therapy

Phase 3 missed primary endpoint

SK Securities 2020

Peer Comparison FY2025

MetricCorestemChemonBiotoxtechHLB BiostepKolmar Biotech

Revenue H1 2026 (KRW Bn)

9.726.329.522.0

Revenue growth YoY (%)

-16.426-643

Operating margin (%)

-105.2-7.6-15.31.8

Company Snapshot

$14.2M

Revenue

391

Employees

2003

Founded

Seongnam, South Korea

Headquarters

SWOT Analysis

Strengths

  • Pioneer CRO franchise: ChemOn founded Jan 2000 as Korea's first private non-clinical CRO, running 1,000–1,500 studies/year (IR deck, Sep 2024).
  • Recurring order recovery: H1 2026 new CRO orders of KRW 15.2 bn, +69% YoY from KRW 9.0 bn (thebell, Sep 2026).
  • Visible backlog: KRW 12.7 bn unrecognised backlog at 30 Jun 2026 out of KRW 27.2 bn total active contracts (thebell).
  • Preserved Korean authorisation: MFDS approved NeuroNata-R label change in May 2026, keeping the product on market (Money Today).
  • Long-term safety dataset: 400+ patients treated since 2014 (Money Today, Jun 2026).
  • Modern manufacturing asset: Osong cGMP with 600 lots/year capacity, designed to FDA standards, with key MFDS permits obtained (IR deck; Money Today).
  • Government validation: ≥KRW 5.4 bn national R&D projects awarded in 2026 (thebell).

Weaknesses

  • Chronic losses: Operating losses every year FY2021–FY2025; FY2025 op loss KRW 21.2 bn exceeded revenue of KRW 20.2 bn (Butler).
  • Liquidity: Cash KRW 2.1 bn vs KRW 24.1 bn borrowings due within one year at end-FY2025 (IB Tomato).
  • Revenue concentration: CRO = 98% of revenue (H1 2026) (thebell).
  • Sub-scale: H1 2026 revenue one-third of Biotoxtech's and HLB Biostep's (Bizwatch).
  • Failed pivotal trial: Phase 3 primary endpoints missed (p=0.118, p=0.339) (Finance Scope).
  • Impaired merger value: KRW 3.9 bn ChemOn goodwill fully written off (IB Tomato).
  • Low insider alignment: Controlling shareholder at 8.17% after selling shares into the rights issue (Digital Today).

Opportunities

  • US BLA without a new trial if FDA accepts subgroup and biomarker data (company expectation; Edaily, Apr 2026).
  • RMAT designation could accelerate FDA interaction (Money Today, Jun 2026).
  • Out-licensing of NeuroNata-R pre-approval, cited as a funding source (IB Tomato).
  • Medical-device testing demand rising fastest (thebell, Sep 2026).
  • Overseas CRO (Vietnam contract) and adjacent industries (functional food, cosmetics).
  • Operating leverage: Q2 2026 gross loss cut 91% on 24% QoQ revenue growth (thebell).
  • Pipeline optionality: NMO, MSA, cerebellar ataxia, lupus, Parkinson's, fibrosis programmes (IR deck).

Threats

  • FDA rejection risk: Post-hoc subgroup claims historically face high scepticism; Type C outcome due late 2026.
  • Refinancing risk: Worst-case sale of Osong or CRO division cited in the 2025 securities statement (IB Tomato).
  • KOSDAQ delisting/administrative designation: Stricter 2026 KOSDAQ exit rules (thebell, Jan 2026); the company has had to manage pre-tax-loss criteria (thebell, Sep 2025).
  • Further dilution: Exchangeable bonds exercised Sep 2026; repeated equity raises (Butler).
  • Competitive recovery gap: Peers grew 26–43% in H1 2026 while CorestemChemon declined 16% (Bizwatch).
  • Evolving ALS standard of care and regulatory shift away from animal studies.
  • Restart execution: Comparability study between Yongin and Osong is a prerequisite for commercial production (Money Today).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
18 Dec 2024Phase 3 topline: primary endpoints missed Finance ScopeFundamental reset of equity story
Q1 2025NeuroNata-R manufacturing suspended IB TomatoCell-therapy revenue collapses ~80% in FY2025
25 Mar 2025Additional biomarker analysis: MCP-1 correlated with treatment response, released before AGM Korea Economic DailySupports post-hoc subgroup thesis
Mar 2025Annual general meeting Korea Economic Daily—
Apr 2025MFDS label-change application filed (narrow to slow progressors) thebellPath to retain Korean authorisation
14 May 2025Press criticism of treasury-share usage as funding tool IB Tomato (headline)Governance controversy
Jul 2025MFDS requests supplementary data; deadline 1 Sep later extended to 31 Oct thebellRegulatory delay
14 Aug 2025H1 2025 report: revenue KRW 11.6 bn (-25%), operating loss ~KRW 10.7 bn, OCF -KRW 7.8 bn Daily Pharm; thebellLargest H1 loss among 10 major Korean CROs
18 Aug 2025Board approves KRW 37.8 bn shareholder rights offering (20 m shares, 0.712 per share, prelim. price KRW 1,890) Smart Today; Digital TodayShares fall >20% to 52-week low next day
18 Sep 2025Rights record date Digital Today—
30 Sep 2025Lower first-round issue price reduces gross proceeds; company says KOSDAQ pre-tax-loss risk still resolved thebellListing-maintenance risk mitigation
13–21 Oct 2025Controlling shareholder sells rights certificates and 796,187 shares at KRW 1,520 Digital TodayInsider stake falls to 8.17%
16–22 Oct 2025Directors Lee Tae-yong and Kim Moon-soon sell rights certificates Digital TodayInsider selling signal
29 Oct 2025Final issue price fixed (lower of first and second prices) Digital Today—
3 Nov 2025Company denies reports of CRO division sale and abandonment of FDA approval thebellRumour management
3–4 Nov 2025Existing-shareholder subscription Digital Today—
11 Nov 2025Payment date; ~KRW 26.1 bn raised (KRW 19.1 bn debt, KRW 6.3 bn operations) IB TomatoDeleveraging
24 Nov 2025New shares listed Digital TodayShare count ~52.9 m (derived)
22 Jan 2026CEO declares 2026 a "first year of growth"; Osong physical readiness targeted in Q1 thebellManagement outlook
Mar 2026FY2025 business report: revenue KRW 20.2 bn (-29.9%), op loss KRW 21.2 bn, net loss KRW 26.8 bn, cash KRW 2.1 bn, goodwill fully impaired IB Tomato; ButlerLiquidity concern
Mar 2026AGM: management says CRO revenue trending up since Q4 2025 IB Tomato—
1 Apr 2026Bulk-holding (5%+) report filed Butler–
8 Apr 2026Press flags liquidity "warning light" IB TomatoInvestor sentiment
13 Apr 2026Company expects Central Pharmaceutical Affairs Council review in Q2 Money TodayApproval catalyst
~21 Apr 2026CPAC deliberation reported; failure would likely end Korean sales EdailyBinary event
15 May 2026Q1 2026 report (revenue KRW 4.3 bn; cost-of-sales ratio 136%) Butler; thebellTrough quarter
26 May 2026MFDS approves NeuroNata-R label change (disclosure) Butler; Money TodayKorean authorisation preserved
4 Jun 2026Company announces commercial production and US push; Osong permits secured; Vietnam CRO contract Money TodayCommercial restart roadmap
8 Jul 2026Officer/major-shareholder ownership report Butler—
4 Aug 2026FDA Type C meeting requested; BLA targeted 2027 Money TodayUS pathway catalyst
14 Aug 2026H1 2026 report: revenue KRW 9.7 bn, op loss KRW 10.2 bn; CRO backlog KRW 12.7 bn thebell; BizwatchRevenue still down YoY
2 Sep 2026H1 CRO new orders KRW 15.2 bn (+69% YoY) thebellLeading indicator of recovery
3 Sep 2026Bulk-holding and insider ownership reports Butler—
4 Sep 2026Exchange claims exercised on 2nd–4th exchangeable bonds ButlerTreasury-share supply / dilution of float
By end-Oct 2026 (expected)FDA Type C meeting; written minutes within 30 days Money TodayNear-term catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Segment (FY2023–FY2025): Total revenue fell from KRW 33,700 Mn in FY2023 to KRW 20,200 Mn in FY2025.
ChemOn Inc. — Revenue by Segment (FY2023–FY2025)
Series (KRW Mn)FY2023FY2024FY2025
Total revenue33,70028,80020,200
Non-clinical CRO revenue31,80027,50019,800
Cell therapy and other revenue1,9001,300400

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. IB Tomato / NewsTomato, "CRO slump and therapy production halt" — 8 Apr 2026 — FY2025 segment revenue, cash, borrowings, rights-issue use of proceeds, goodwill impairment, Yongin utilisation
  2. thebell / Money Today, "Non-clinical CRO order recovery" — 2 Sep 2026 — H1 2026 results, orders, backlog, quarterly margins, government projects
  3. thebell / Money Today, "Growth year" — 22 Jan 2026 — CEO statements, merger year
  4. thebell / Money Today, rights-issue series — 2 Oct 2025; 5 Nov 2025 — H1 2025 data, OCF, MFDS timeline, rumour denial
  5. Money Today, commercial production and US push — 4 Jun 2026 — Label-change approval, Osong permits, ALS market, Vietnam contract
  6. Money Today, FDA Type C request — 4 Aug 2026 — US strategy, BLA 2027 target
  7. Money Today, 22-year development — 13 Apr 2026 — CPAC timing, US sales estimate
  8. Edaily (via Daum), CPAC deliberation — 22 Apr 2026 — Approval risk
  9. Finance Scope, Phase 3 topline — 18 Dec 2024 — Phase 3 results and p-values
  10. Korea Economic Daily, MCP-1 biomarker — 25 Mar 2025 — Biomarker analysis
  11. Bizwatch, CRO H1 results — 18 Aug 2026 — Peer benchmarking
  12. Daily Pharm, CRO H1 2025 results — Aug 2025 — H1 2025 losses vs peers
  13. Medical Times; Biospectator — Aug 2022 — Merger terms and rationale
  14. Digital Today (DART AI summaries) — Oct 2025 — Ownership changes, FY2024 balance sheet, rights-issue terms, listing date
  15. Smart Today — 19 Aug 2025 — Rights-offering size and market reaction
  16. CorestemChemon IR decks — Apr, Jun, Sep 2024 — Structure, pipeline, Phase 3 design, Osong, employees, HQ
  17. SK Securities research — Mar, Aug, Dec 2020 — Historical revenue mix, ownership, MGH expanded access
  18. Korea IR Council research — Jul 2024 — History, AAALAC
  19. Butler (DART-derived aggregator) — Oct 2026 — Five-year P&L, market cap, P/B, ROE, treasury ratio, disclosure list
  20. CB Insights; Dealroom— ChemOn founding, SPAC listing, Instem deployment
  21. Asia Business Daily — Jun 2020 — Corestem CB issuance
  22. iNews24 — Jun 2015 — Corestem IPO context

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.